Fiche société
University of Pennsylvania
Traitements, essais et publications liés.
Traitements25programmes
Essais12liés
Publications37liées
SourceDBlocale
Traitements
25| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| 3T Magnetic Resonance Imaging (MRI)The overarching goal of this study is to improve understanding of the long-range natural history of TBI and post-traumatic epilepsy (PTE) by extending follow-up of a previously enrolled cohort (TRACK-TBI) beyond the first 12 months after injury. | Épilepsie | À vérifier | À vérifier | United States | À vérifier |
| BexxarPatients with B-cell lymphoma who relapse after autologous transplant tend to have a poor prognosis. Currently, there is no standard treatment for such patients. Bexxar is a radioactive antibody therapy that has shown a 60-80% response rate in non-transplanted patients with relapsed B-cell lymphoma. This study will test the safety and efficacy of Bexxar in the treatment of patients whose B-cell lymphoma has relapsed after an autologous transplant. | SEP | Phase 1 | United States | À vérifier | |
| Blood DrawThe overarching goal of this study is to improve understanding of the long-range natural history of TBI and post-traumatic epilepsy (PTE) by extending follow-up of a previously enrolled cohort (TRACK-TBI) beyond the first 12 months after injury. | Épilepsie | À vérifier | À vérifier | United States | À vérifier |
| BRAIN — Biofluid Research on Age-Related or Inherited NeurodegenerationThe aim of this study is to contribute to and continue to sustain a repository of blood samples, nucleic acid (DNA and/or RNA) samples, family history information, and other demographic information from individuals with age-related neurodegenerative conditions, or their family members who may or may not be at risk for similar conditions. This study will continue to further expand research into the molecular and genetic basis of these diseases and their risk factors. | Alzheimer, Sclérose latérale amyotrophique | À vérifier | À vérifier | United States | À vérifier |
| CART-19This is a randomized, open-label, parallel group study to determine the optimal dose of CART-19 cells (autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR Zeta and 4-1 BB co-stimulatory domains) of the two dose levels being assessed (1-5x10e8 vs. 1-5x10e7 CART-19 cells). This trial will be conducted in two stages. | SEP | Phase 2 | Immunomodulation | United States | À vérifier |
| EEGSystemic lupus erythematosus (SLE) is a chronic autoimmune disease involving multiple organs, characterized by the production of autoantibodies and the development of tissue injury. The etiology of SLE is partially known, involving multiple genetic and environmental factors. As many as 50% of patients with SLE have neurological involvement during the course of their disease. Approximately 40% of neuropsychiatric SLE (NPSLE) cases are a consequence of the disease itself; other causes of NPSLE are infections, metabolic disorders, and side effects of drugs. The American College of Rheumatology identified 19 neuropsychiatric syndromes in SLE patients that can be divided into central and peripheral nervous system manifestations. Although this classification includes syndromes with no clear pathophysiological mechanism and is not specific for neuropsychiatric events caused exclusively by SLE, it helps the physician to recognize any neurological involvement . The most common clinical manifestations of juvenile neuropsychiatric SLE (NPSLE) are headache, cognitive dysfunction, mood disturbances and seizures. The pathophysiology of juvenile NPSLE is not yet fully known, but immunological and inflammatory factors, such as autoantibodies, cytokine and prothrombotic states are widely described . The of autoantibodies in the onset of specific clinical manifestations has also been recognized. Juvenile NPSLE manifestations are often difficult to diagnose (. Nineteen neuropsychiatric syndromes have been identified associated with SLE, can be divided into central and peripheral manifestations. | Alzheimer, Épilepsie, Lupus, Parkinson | À vérifier | Immunomodulation | United States | À vérifier |
| Everolimus Oral ProductThe purpose of this research study is to see if simvastatin can be taken safely in patients with either LAM or TSC, who are already being treated with everolimus or sirolimus. This is the first step in looking at simvastatin as a drug that may help patients, by impacting the growth and survival of cells that make up the lung lesions that cause problems in LAM and TSC patients. The study also seeks to learn more about how simvastatin works, when given to patients being treated with everolimus or sirolimus, and to evaluate the safety and any potential benefit to patients taking this 2-drug combination. The primary objective of this study is to determine the safety of simvastatin in the treatment of LAM-S or LAM-TS in patients on a stable (for at least 3 months) dose of sirolimus or everolimus. Secondary objectives include: * To assess the effect of simvastatin on forced expiratory volume in 1 second (FEV1). * To assess the effect of simvastatin on forced vital capacity (FVC). * To assess the effect of simvastatin on diffusing lung capacity (DLCO). * To assess the effect of simvastatin on vascular endothelial growth factor -D (VEGF-D) serum levels. * To assess the effect of simvastatin with questionnaire- based assessments of dyspnea, fatigue, and quality of life (QOL). * Assess signs of clinical benefit. | SEP | Phase 1 | Traitement symptomatique | United States | À vérifier |
| Mechanical insufflationDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Non applicable | À vérifier | United States | À vérifier |
| Non-invasive ventilationDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 2 | Traitement symptomatique | United States | À vérifier |
| SimvastatinThe purpose of this research study is to see if simvastatin can be taken safely in patients with either LAM or TSC, who are already being treated with everolimus or sirolimus. This is the first step in looking at simvastatin as a drug that may help patients, by impacting the growth and survival of cells that make up the lung lesions that cause problems in LAM and TSC patients. The study also seeks to learn more about how simvastatin works, when given to patients being treated with everolimus or sirolimus, and to evaluate the safety and any potential benefit to patients taking this 2-drug combination. The primary objective of this study is to determine the safety of simvastatin in the treatment of LAM-S or LAM-TS in patients on a stable (for at least 3 months) dose of sirolimus or everolimus. Secondary objectives include: * To assess the effect of simvastatin on forced expiratory volume in 1 second (FEV1). * To assess the effect of simvastatin on forced vital capacity (FVC). * To assess the effect of simvastatin on diffusing lung capacity (DLCO). * To assess the effect of simvastatin on vascular endothelial growth factor -D (VEGF-D) serum levels. * To assess the effect of simvastatin with questionnaire- based assessments of dyspnea, fatigue, and quality of life (QOL). * Assess signs of clinical benefit. | SEP | Phase 1 | Traitement symptomatique | United States | À vérifier |
| Sirolimus Oral ProductThe purpose of this research study is to see if simvastatin can be taken safely in patients with either LAM or TSC, who are already being treated with everolimus or sirolimus. This is the first step in looking at simvastatin as a drug that may help patients, by impacting the growth and survival of cells that make up the lung lesions that cause problems in LAM and TSC patients. The study also seeks to learn more about how simvastatin works, when given to patients being treated with everolimus or sirolimus, and to evaluate the safety and any potential benefit to patients taking this 2-drug combination. The primary objective of this study is to determine the safety of simvastatin in the treatment of LAM-S or LAM-TS in patients on a stable (for at least 3 months) dose of sirolimus or everolimus. Secondary objectives include: * To assess the effect of simvastatin on forced expiratory volume in 1 second (FEV1). * To assess the effect of simvastatin on forced vital capacity (FVC). * To assess the effect of simvastatin on diffusing lung capacity (DLCO). * To assess the effect of simvastatin on vascular endothelial growth factor -D (VEGF-D) serum levels. * To assess the effect of simvastatin with questionnaire- based assessments of dyspnea, fatigue, and quality of life (QOL). * Assess signs of clinical benefit. | SEP | Phase 1 | Traitement symptomatique | United States | À vérifier |
| Using the EHR to Advance Genomic Medicine Across a Diverse Health SystemGiven the expansion of indications for genetic testing and our understanding of conditions for which the results change medical management, it is imperative to consider novel ways to deliver care beyond the traditional genetic counseling visit, which are both amenable to large-scale implementation and sustainable. The investigators propose an entirely new approach for the implementation of genomic medicine, supported by the leadership of Penn Medicine, investigating the use of non-geneticist clinician and patient nudges in the delivery of genomic medicine through a pragmatic randomized clinical trial, addressing NHGRI priorities. Our application is highly conceptually and technically innovative, building upon expertise and infrastructure already in place. Innovative qualities of our proposal include: 1) Cutting edge EHR infrastructure already built to support genomic medicine (e.g., partnering with multiple commercial genetic testing laboratories for direct test ordering and results reporting in the EHR); 2) Automated EHR-based direct ordering or referring by specialist clinicians (i.e., use of replicable modules that enable specialist clinicians to order genetic testing through Epic Smartsets, including all needed components, such as populated gene lists, smartphrases, genetic testing, informational websites and acknowledgement e-forms for patient signature); 3) EHR algorithms for accurate patient identification (i.e., electronic phenotype algorithms to identify eligible patients, none of which currently have phenotype algorithms present in PheKB; 4) Behavioral economics-informed implementation science methods: This trial will be the first to evaluate implementation strategies informed by behavioral economics, directed at clinicians and/or patients, for increasing the use of genetic testing; further it will be the first study in this area to test two forms of defaults as a potential local adaptation to facilitate implementation (ordering vs. referring); and 5) Dissemination: In addition to standard dissemination modalities,PheKB95, GitHub and Epic Community Library, the investigators propose to disseminate via AnVIL (NHGRI's Genomic Data Science Analysis, Visualization, and Informatics Lab-Space). Our results will represent an entirely new paradigm for the provision of genomic medicine for patients in whom the results of genetic testing change medical management. | Alzheimer, Cancer, Parkinson, Sclérose latérale amyotrophique | Non applicable | À vérifier | United States | À vérifier |
| Veech Ketone Ester to Support Brain Energy in Mild Cognitive Impairment and Early Alzheimer's DiseaseIt is projected that by 2030, one in every five Americans will be of retirement age, and this demographic shift is expected to result in more people suffering from dementia. A key feature of the brain is its need for a constant supply of glucose and oxygen to meet the high energy costs of mental activity. This study aims to develop clinically practical, noninvasive imaging methods based on combined positron emission tomography and magnetic resonance imaging to assess brain energy in order to better understand how this critical component of brain health is impacted by aging. | Alzheimer | Non applicable | À vérifier | Canada | À vérifier |
| EEGSystemic lupus erythematosus (SLE) is a chronic autoimmune disease involving multiple organs, characterized by the production of autoantibodies and the development of tissue injury. The etiology of SLE is partially known, involving multiple genetic and environmental factors. As many as 50% of patients with SLE have neurological involvement during the course of their disease. Approximately 40% of neuropsychiatric SLE (NPSLE) cases are a consequence of the disease itself; other causes of NPSLE are infections, metabolic disorders, and side effects of drugs. The American College of Rheumatology identified 19 neuropsychiatric syndromes in SLE patients that can be divided into central and peripheral nervous system manifestations. Although this classification includes syndromes with no clear pathophysiological mechanism and is not specific for neuropsychiatric events caused exclusively by SLE, it helps the physician to recognize any neurological involvement . The most common clinical manifestations of juvenile neuropsychiatric SLE (NPSLE) are headache, cognitive dysfunction, mood disturbances and seizures. The pathophysiology of juvenile NPSLE is not yet fully known, but immunological and inflammatory factors, such as autoantibodies, cytokine and prothrombotic states are widely described . The of autoantibodies in the onset of specific clinical manifestations has also been recognized. Juvenile NPSLE manifestations are often difficult to diagnose (. Nineteen neuropsychiatric syndromes have been identified associated with SLE, can be divided into central and peripheral manifestations. | Lupus | À vérifier | Immunomodulation | Egypt | À vérifier |
| SimvastatinThe purpose of this research study is to see if simvastatin can be taken safely in patients with either LAM or TSC, who are already being treated with everolimus or sirolimus. This is the first step in looking at simvastatin as a drug that may help patients, by impacting the growth and survival of cells that make up the lung lesions that cause problems in LAM and TSC patients. The study also seeks to learn more about how simvastatin works, when given to patients being treated with everolimus or sirolimus, and to evaluate the safety and any potential benefit to patients taking this 2-drug combination. The primary objective of this study is to determine the safety of simvastatin in the treatment of LAM-S or LAM-TS in patients on a stable (for at least 3 months) dose of sirolimus or everolimus. Secondary objectives include: * To assess the effect of simvastatin on forced expiratory volume in 1 second (FEV1). * To assess the effect of simvastatin on forced vital capacity (FVC). * To assess the effect of simvastatin on diffusing lung capacity (DLCO). * To assess the effect of simvastatin on vascular endothelial growth factor -D (VEGF-D) serum levels. * To assess the effect of simvastatin with questionnaire- based assessments of dyspnea, fatigue, and quality of life (QOL). * Assess signs of clinical benefit. | SEP | Phase 1 | Traitement symptomatique | United States | À vérifier |
| EEGSystemic lupus erythematosus (SLE) is a chronic autoimmune disease involving multiple organs, characterized by the production of autoantibodies and the development of tissue injury. The etiology of SLE is partially known, involving multiple genetic and environmental factors. As many as 50% of patients with SLE have neurological involvement during the course of their disease. Approximately 40% of neuropsychiatric SLE (NPSLE) cases are a consequence of the disease itself; other causes of NPSLE are infections, metabolic disorders, and side effects of drugs. The American College of Rheumatology identified 19 neuropsychiatric syndromes in SLE patients that can be divided into central and peripheral nervous system manifestations. Although this classification includes syndromes with no clear pathophysiological mechanism and is not specific for neuropsychiatric events caused exclusively by SLE, it helps the physician to recognize any neurological involvement . The most common clinical manifestations of juvenile neuropsychiatric SLE (NPSLE) are headache, cognitive dysfunction, mood disturbances and seizures. The pathophysiology of juvenile NPSLE is not yet fully known, but immunological and inflammatory factors, such as autoantibodies, cytokine and prothrombotic states are widely described . The of autoantibodies in the onset of specific clinical manifestations has also been recognized. Juvenile NPSLE manifestations are often difficult to diagnose (. Nineteen neuropsychiatric syndromes have been identified associated with SLE, can be divided into central and peripheral manifestations. | Épilepsie | Non applicable | Immunomodulation | United States | À vérifier |
| Mechanical insufflationDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Non applicable | À vérifier | United States | À vérifier |
| 3T Magnetic Resonance Imaging (MRI)The overarching goal of this study is to improve understanding of the long-range natural history of TBI and post-traumatic epilepsy (PTE) by extending follow-up of a previously enrolled cohort (TRACK-TBI) beyond the first 12 months after injury. | Épilepsie | À vérifier | À vérifier | United States | À vérifier |
| Non-invasive ventilationDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 2 | Traitement symptomatique | United States | À vérifier |
| Using the EHR to Advance Genomic Medicine Across a Diverse Health SystemGiven the expansion of indications for genetic testing and our understanding of conditions for which the results change medical management, it is imperative to consider novel ways to deliver care beyond the traditional genetic counseling visit, which are both amenable to large-scale implementation and sustainable. The investigators propose an entirely new approach for the implementation of genomic medicine, supported by the leadership of Penn Medicine, investigating the use of non-geneticist clinician and patient nudges in the delivery of genomic medicine through a pragmatic randomized clinical trial, addressing NHGRI priorities. Our application is highly conceptually and technically innovative, building upon expertise and infrastructure already in place. Innovative qualities of our proposal include: 1) Cutting edge EHR infrastructure already built to support genomic medicine (e.g., partnering with multiple commercial genetic testing laboratories for direct test ordering and results reporting in the EHR); 2) Automated EHR-based direct ordering or referring by specialist clinicians (i.e., use of replicable modules that enable specialist clinicians to order genetic testing through Epic Smartsets, including all needed components, such as populated gene lists, smartphrases, genetic testing, informational websites and acknowledgement e-forms for patient signature); 3) EHR algorithms for accurate patient identification (i.e., electronic phenotype algorithms to identify eligible patients, none of which currently have phenotype algorithms present in PheKB; 4) Behavioral economics-informed implementation science methods: This trial will be the first to evaluate implementation strategies informed by behavioral economics, directed at clinicians and/or patients, for increasing the use of genetic testing; further it will be the first study in this area to test two forms of defaults as a potential local adaptation to facilitate implementation (ordering vs. referring); and 5) Dissemination: In addition to standard dissemination modalities,PheKB95, GitHub and Epic Community Library, the investigators propose to disseminate via AnVIL (NHGRI's Genomic Data Science Analysis, Visualization, and Informatics Lab-Space). Our results will represent an entirely new paradigm for the provision of genomic medicine for patients in whom the results of genetic testing change medical management. | Sclérose latérale amyotrophique | Non applicable | À vérifier | United States | À vérifier |
| Veech Ketone Ester to Support Brain Energy in Mild Cognitive Impairment and Early Alzheimer's DiseaseIt is projected that by 2030, one in every five Americans will be of retirement age, and this demographic shift is expected to result in more people suffering from dementia. A key feature of the brain is its need for a constant supply of glucose and oxygen to meet the high energy costs of mental activity. This study aims to develop clinically practical, noninvasive imaging methods based on combined positron emission tomography and magnetic resonance imaging to assess brain energy in order to better understand how this critical component of brain health is impacted by aging. | Alzheimer | Non applicable | À vérifier | Canada | À vérifier |
| BRAIN — Biofluid Research on Age-Related or Inherited NeurodegenerationThe aim of this study is to contribute to and continue to sustain a repository of blood samples, nucleic acid (DNA and/or RNA) samples, family history information, and other demographic information from individuals with age-related neurodegenerative conditions, or their family members who may or may not be at risk for similar conditions. This study will continue to further expand research into the molecular and genetic basis of these diseases and their risk factors. | Sclérose latérale amyotrophique | À vérifier | À vérifier | United States | À vérifier |
| BexxarPatients with B-cell lymphoma who relapse after autologous transplant tend to have a poor prognosis. Currently, there is no standard treatment for such patients. Bexxar is a radioactive antibody therapy that has shown a 60-80% response rate in non-transplanted patients with relapsed B-cell lymphoma. This study will test the safety and efficacy of Bexxar in the treatment of patients whose B-cell lymphoma has relapsed after an autologous transplant. | SEP | Phase 1 | United States | À vérifier | |
| EEGSystemic lupus erythematosus (SLE) is a chronic autoimmune disease involving multiple organs, characterized by the production of autoantibodies and the development of tissue injury. The etiology of SLE is partially known, involving multiple genetic and environmental factors. As many as 50% of patients with SLE have neurological involvement during the course of their disease. Approximately 40% of neuropsychiatric SLE (NPSLE) cases are a consequence of the disease itself; other causes of NPSLE are infections, metabolic disorders, and side effects of drugs. The American College of Rheumatology identified 19 neuropsychiatric syndromes in SLE patients that can be divided into central and peripheral nervous system manifestations. Although this classification includes syndromes with no clear pathophysiological mechanism and is not specific for neuropsychiatric events caused exclusively by SLE, it helps the physician to recognize any neurological involvement . The most common clinical manifestations of juvenile neuropsychiatric SLE (NPSLE) are headache, cognitive dysfunction, mood disturbances and seizures. The pathophysiology of juvenile NPSLE is not yet fully known, but immunological and inflammatory factors, such as autoantibodies, cytokine and prothrombotic states are widely described . The of autoantibodies in the onset of specific clinical manifestations has also been recognized. Juvenile NPSLE manifestations are often difficult to diagnose (. Nineteen neuropsychiatric syndromes have been identified associated with SLE, can be divided into central and peripheral manifestations. | Parkinson | Non applicable | Immunomodulation + Traitement symptomatique | France | À vérifier |
| CART-19This is a randomized, open-label, parallel group study to determine the optimal dose of CART-19 cells (autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR Zeta and 4-1 BB co-stimulatory domains) of the two dose levels being assessed (1-5x10e8 vs. 1-5x10e7 CART-19 cells). This trial will be conducted in two stages. | SEP | Phase 2 | Immunomodulation | United States | À vérifier |
Essais cliniques
12| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| CART-19 | SEP | Phase 2 | NCT01747486 | Dose Optimization Trial of CD19 Redirected Autologous T Cells | COMPLETED |
| EEG | Parkinson | Non applicable | NCT05808504 | STIMPARK — Investigation of the Benefits of Electrical Non-invasive Stimulation on Cognitive Symptoms in Parkinson's Disease | ACTIVE_NOT_RECRUITING |
| Bexxar | SEP | Phase 1 | NCT00434629 | Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant | COMPLETED |
| BRAIN — Biofluid Research on Age-Related or Inherited Neurodegeneration | Sclérose latérale amyotrophique | À vérifier | NCT07798700 | BRAIN — Biofluid Research on Age-Related or Inherited Neurodegeneration | RECRUITING |
| Veech Ketone Ester to Support Brain Energy in Mild Cognitive Impairment and Early Alzheimer's Disease | Alzheimer | Non applicable | NCT06767124 | Veech Ketone Ester to Support Brain Energy in Mild Cognitive Impairment and Early Alzheimer's Disease | NOT_YET_RECRUITING |
| Using the EHR to Advance Genomic Medicine Across a Diverse Health System | Sclérose latérale amyotrophique | Non applicable | NCT06377033 | Using the EHR to Advance Genomic Medicine Across a Diverse Health System | RECRUITING |
| Non-invasive ventilation | Sclérose latérale amyotrophique | Phase 2 | NCT07071935 | A Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS) | RECRUITING |
| 3T Magnetic Resonance Imaging (MRI) | Épilepsie | À vérifier | NCT05823766 | Transforming Research and Clinical Knowledge in Traumatic Brain Injury Epileptogenesis Project (TRACK-TBI EPI) | ACTIVE_NOT_RECRUITING |
| Mechanical insufflation | Sclérose latérale amyotrophique | Non applicable | NCT06119087 | Mechanical Insufflation in the Philadelphia Amyotrophic Lateral Sclerosis Cohort (MI-PALS) Study | COMPLETED |
| EEG | Épilepsie | Non applicable | NCT06934356 | Subcortical Arousal in Perceptual Awareness | RECRUITING |
| Simvastatin | SEP | Phase 1 | NCT02061397 | Safety of Simvastatin in LAM and TSC | COMPLETED |
| EEG | Lupus | À vérifier | NCT06449794 | Neuropsycatric Disorders Among Children With Systemic Lupus Erythematosus in Sohag University Hospital | UNKNOWN |
Publications
37| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| BRAIN — Biofluid Research on Age-Related or Inherited Neurodegeneration | From food to function: Nutraceutical-based modulation of mitochondrial, inflammatory and epigenetic networks in retinal neurodegeneration. | Ageing research reviews | ||
| BRAIN — Biofluid Research on Age-Related or Inherited Neurodegeneration | Spectrum Disorders: Genetic Complexity Beyond Dominant Inheritance. | Neurology. Genetics | ||
| BRAIN — Biofluid Research on Age-Related or Inherited Neurodegeneration | Omics in hereditary optic neuropathies: A systematic review of clinical studies with an integrated point of view. | Survey of ophthalmology | ||
| Blood Draw | Blood metabolomic signatures linking air pollution to lung cancer in the Cancer Prevention Studies. | Nature communications | ||
| Blood Draw | Non-invasive nanoparticle barcoding in nonhuman primates. | Nature biotechnology | ||
| Blood Draw | Serum as an alternative to plasma for determining the ApoE4 phenotype using Pan-ApoE and ApoE4 chemiluminescent enzyme immunoassays. | Clinical chemistry and laboratory medicine | ||
| 3T Magnetic Resonance Imaging (MRI) | Freehand 3T MR-guided vacuum-assisted breast biopsy (VAB): a five-year experience. | Acta radiologica (Stockholm, Sweden : 1987) | ||
| 3T Magnetic Resonance Imaging (MRI) | A robust broadband fat-suppressing phaser T -preparation module for cardiac magnetic resonance imaging at 3T. | Magnetic resonance in medicine | ||
| Non-invasive ventilation | Optimizing Non-invasive Ventilation in Acute Respiratory Failure. | Clinics in chest medicine | ||
| Non-invasive ventilation | Optimizing Care in Respiratory Infections: Advanced Approaches to Mechanical Ventilation. | Critical care nursing clinics of North America | ||
| Non-invasive ventilation | Prehospital PEEP for Acute Respiratory Distress: Protocol for a Scoping Review. | Acta anaesthesiologica Scandinavica | ||
| Mechanical insufflation | Tracheostomy Tube Decannulation and Noninvasive Ventilatory Support For Traumatic Tetraplegia. | American journal of physical medicine & rehabilitation | ||
| Mechanical insufflation | Reversal of lung consolidation with mechanical insufflation-exsufflation in a brain-dead lung donor. | JHLT open | ||
| Mechanical insufflation | NIV Versus NVS: A Review of Respiratory Principles of Physical Medicine After 60 Years of Neglect. | American journal of physical medicine & rehabilitation | ||
| EEG | A Time-Frequency Decoupled Contrastive Learning Framework for Electroencephalography-Based Parkinson's Disease Diagnosis. | International journal of neural systems | ||
| EEG | Automatic Seizure Detection using Hierarchical Spectral-Temporal Feature Learning with an Imbalance-Aware Transformer. | International journal of neural systems | ||
| EEG | ETAS reduces wake time after sleep onset in healthy adults who are dissatisfied with their sleep: A randomized, placebo-controlled, double-blind crossover study. | Sleep medicine: X | ||
| Everolimus Oral Product | mTOR signaling is required for phagocyte free radical production, GLUT1 expression, and control of infection. | mBio | ||
| Everolimus Oral Product | Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer. | Cancer research | ||
| Sirolimus Oral Product | Pharmacokinetic analysis of intermittent rapamycin administration in early-stage Alzheimer's Disease. | GeroScience | ||
| Simvastatin | Macrophage autophagy in allergic diseases: Regulatory mechanisms, immune crosstalk, and therapeutic implications. | International immunopharmacology | ||
| Simvastatin | Interaction between amphiphilic drugs and biofilms revealed by surface-enhanced Raman spectroscopy. | Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy | ||
| EEG | EEG-Guided Sevoflurane Anesthesia and Emergence Delirium in Children: A Randomized Controlled Trial. | Paediatric anaesthesia | ||
| EEG | EXPRESS: Baseline Electrophysiology versus Oxidative Metabolism as Traits of Inter-Network Differences in Neurometabolic Association. | Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism | ||
| Simvastatin | Mechanisms and Predisposing Conditions for Statin-Induced New-Onset Type 2 Diabetes Mellitus: A Paradox Relative to Their Pleiotropic Metabolic Effects. | Endocrinology, diabetes & metabolism | ||
| Simvastatin | Cholesterol synthesis inhibitors effectively inhibit the replication of African swine fever virus in vitro. | Virology | ||
| Everolimus Oral Product | Analysis of the Main Directions in the Development of Mono and Combination Pharmacotherapy Acting on Hormonal Signaling Pathways of Breast Cancer According to the FDA Databases and Clinicaltrials.gov. | Current medicinal chemistry | ||
| Sirolimus Oral Product | Learnings from Patient Mortality after Delandistrogene Moxeparvovec Administration: A Report of Two Cases and Expert Committee Considerations for Future Mitigation and Management. | Human gene therapy | ||
| Sirolimus Oral Product | Intravenous Everolimus Formulation (Sapu003) for Clinical Trials. | International journal of molecular sciences | ||
| Simvastatin | Pharmacogenomic landscape in Thailand: Array-based profiling and EMR-linked medication exposure. | PloS one | ||
| Simvastatin | Patient-specific iPSC-derived ECs identify QKI-7 as a key regulator of endothelial dysfunction and potential therapeutic target in diabetes. | Stem cells translational medicine | ||
| EEG | Cross-task, explainable and real-time decoding of human emotion states by integrating gray and white matter intracranial neural activity. | Nature computational science | ||
| EEG | Efficacy of oxcarbazepine in treating focal epilepsy based on resting-state EEG functional connectivity and power spectral analyses. | Acta epileptologica | ||
| EEG | EEG emotion recognition using a channel-aware feature encoder and XGBoost classifier. | Computer methods in biomechanics and biomedical engineering | ||
| EEG | Successful transcranial motor evoked potentials monitoring under remimazolam-based anaesthesia: Case reports of two patients. | Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia | ||
| EEG | Todd's Paralysis Simulating Acute Ischemic Stroke: A Case Report. | Cureus | ||
| EEG | A randomised controlled trial comparing the effects of transcranial pulse stimulation and EEG neurofeedback on sustained attention and depressive symptoms in young adults. | International journal of clinical and health psychology : IJCHP |